[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HN2012000973A - INHIBIDORES DE N1-PIRAZOLOESPIROCETONA ACETIL-CoA CARBOXILASA - Google Patents

INHIBIDORES DE N1-PIRAZOLOESPIROCETONA ACETIL-CoA CARBOXILASA

Info

Publication number
HN2012000973A
HN2012000973A HN2012000973A HN2012000973A HN2012000973A HN 2012000973 A HN2012000973 A HN 2012000973A HN 2012000973 A HN2012000973 A HN 2012000973A HN 2012000973 A HN2012000973 A HN 2012000973A HN 2012000973 A HN2012000973 A HN 2012000973A
Authority
HN
Honduras
Prior art keywords
pirazoloespirocetona
acetil
coa carboxylase
carboxylase inhibitors
inhibitors
Prior art date
Application number
HN2012000973A
Other languages
English (en)
Inventor
Bagley Scott William
Griffith David Andrew
Kung Daniel Wei-Shung
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of HN2012000973A publication Critical patent/HN2012000973A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A COMPUESTOS DE PIRAZOLOESPIROCETONA SUSTITUIDAS QUE ACTUAN COMO INHIBIDORES DE UNA O MAS ACETIL CoA CARBOXILASA Y A SU USO EN EL TRATAMIENTO DE ENFERMEDADES , AFECCIONES O TRASTORNOS MODULADOS POR LA INHIBICION DE UNA O MAS ENZIMAS ACETIL-CoA CARBOXILASAS
HN2012000973A 2009-11-10 2012-05-07 INHIBIDORES DE N1-PIRAZOLOESPIROCETONA ACETIL-CoA CARBOXILASA HN2012000973A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25982309P 2009-11-10 2009-11-10

Publications (1)

Publication Number Publication Date
HN2012000973A true HN2012000973A (es) 2015-03-02

Family

ID=43357094

Family Applications (1)

Application Number Title Priority Date Filing Date
HN2012000973A HN2012000973A (es) 2009-11-10 2012-05-07 INHIBIDORES DE N1-PIRAZOLOESPIROCETONA ACETIL-CoA CARBOXILASA

Country Status (39)

Country Link
US (4) US8288405B2 (es)
EP (3) EP2947082A1 (es)
JP (1) JP5114610B1 (es)
KR (2) KR101478517B1 (es)
CN (1) CN102695708B (es)
AP (1) AP3283A (es)
AR (1) AR078944A1 (es)
AU (1) AU2010317501B2 (es)
BR (1) BR112012011072A2 (es)
CA (1) CA2778886C (es)
CL (1) CL2012000999A1 (es)
CO (1) CO6541569A2 (es)
CR (1) CR20120190A (es)
CU (1) CU24077B1 (es)
DK (1) DK2499139T3 (es)
DO (1) DOP2012000128A (es)
EA (1) EA020153B1 (es)
EC (1) ECSP12011880A (es)
ES (1) ES2444543T3 (es)
GE (1) GEP20146169B (es)
HK (1) HK1173724A1 (es)
HN (1) HN2012000973A (es)
HR (1) HRP20140025T1 (es)
IL (1) IL219373A (es)
MA (1) MA33734B1 (es)
MX (1) MX2012005429A (es)
NI (1) NI201200089A (es)
NZ (1) NZ599815A (es)
PE (1) PE20121469A1 (es)
PL (1) PL2499139T3 (es)
PT (1) PT2499139E (es)
RS (1) RS53156B (es)
SI (1) SI2499139T1 (es)
TN (1) TN2012000192A1 (es)
TW (1) TWI394756B (es)
UA (1) UA102336C2 (es)
UY (1) UY33020A (es)
WO (1) WO2011058474A1 (es)
ZA (1) ZA201204231B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2297163B1 (en) 2008-05-28 2015-07-08 Pfizer Inc. Pyrazolospiroketone acetyl-CoA carboxylase inhibitors
DK2448938T5 (en) 2009-06-29 2015-10-05 Incyte Corp Pyrimidinones AS PI3K inhibitors
AP3283A (en) 2009-11-10 2015-05-31 Pfizer N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors
US8759359B2 (en) 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
EP2345643A1 (en) * 2009-12-29 2011-07-20 Polichem S.A. New tertiary 8-hydroxyquinoline-7-carboxamide derivatives and uses thereof
EP2558463A1 (en) 2010-04-14 2013-02-20 Incyte Corporation Fused derivatives as i3 inhibitors
WO2011163195A1 (en) 2010-06-21 2011-12-29 Incyte Corporation Fused pyrrole derivatives as pi3k inhibitors
WO2012042433A1 (en) 2010-09-30 2012-04-05 Pfizer Inc. N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS
CN103189377B (zh) 2010-10-29 2015-02-25 辉瑞大药厂 N1/n2-内酰胺乙酰辅酶a羧化酶抑制剂
JP5961187B2 (ja) 2010-12-20 2016-08-02 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｐｉ３ｋ阻害剤としてのｎ−（１−（置換フェニル）エチル）−９ｈ−プリン−６−アミン
WO2012125629A1 (en) 2011-03-14 2012-09-20 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
WO2012135009A1 (en) 2011-03-25 2012-10-04 Incyte Corporation Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
MX348860B (es) 2011-04-22 2017-06-30 Pfizer Derivados de pirazoloespirocetona para usarse como inhibidores de acetil-coa carboxilasa.
JP6067709B2 (ja) 2011-09-02 2017-01-25 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｐｉ３ｋ阻害剤としてのヘテロシクリルアミン
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
WO2014134391A1 (en) 2013-02-28 2014-09-04 Bristol-Myers Squibb Company Phenylpyrazole derivatives as potent rock1 and rock2 inhibitors
TW201444798A (zh) 2013-02-28 2014-12-01 必治妥美雅史谷比公司 作爲強效ｒｏｃｋ１及ｒｏｃｋ２抑制劑之苯基吡唑衍生物
CA2903081A1 (en) 2013-03-14 2014-09-25 Quanticel Pharmaceuticals, Inc. Histone demethylase inhibitors
AU2014319990A1 (en) 2013-09-12 2016-02-25 Pfizer Inc. Use of acetyl-CoA carboxylase inhibitors for treating acne vulgaris
WO2015056782A1 (ja) 2013-10-17 2015-04-23 塩野義製薬株式会社 新規アルキレン誘導体
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
EP3193881B1 (en) 2014-09-16 2022-02-09 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
US9896436B2 (en) 2014-09-16 2018-02-20 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
EP3194387B1 (en) * 2014-09-17 2019-07-31 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
KR102411448B1 (ko) 2014-11-10 2022-06-20 고쿠리츠다이가쿠호진 요코하마 고쿠리츠다이가쿠 산소 발생용 애노드
MD3262046T2 (ro) 2015-02-27 2021-03-31 Incyte Corp Săruri de inhibitori ai PI3K și procedee pentru prepararea lor
WO2016183063A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Crystalline forms of a pi3k inhibitor
US9732097B2 (en) 2015-05-11 2017-08-15 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
JP7142375B2 (ja) 2017-06-30 2022-09-27 クイクスゲン インコーポレイテッド 新規なスピロラクトン化合物及び医薬組成物
DK3713942T3 (da) 2017-11-21 2023-04-03 Pfizer Krystallinsk 2-amino-2-(hydroxymethyl)propan-1,3-diol-salt af 4-(4-(1-isopropyl-7-oxo-1,4,6,7-tetrahydrospiro[indazol-5,4'-piperidin]-1'-carbonyl)-6-methoxypyridin-2-yl)benzoesyre
US11465991B2 (en) 2018-03-15 2022-10-11 Yale University Pyrazole-containing macrophage migration inhibitory factor inhibitors
WO2021235508A1 (ja) 2020-05-21 2021-11-25 塩野義製薬株式会社 脂肪性肝疾患の治療用医薬
US10989621B1 (en) 2020-08-20 2021-04-27 Trinity Bay Equipment Holdings, LLC Online pipe integrity testing system and method
CN112028834B (zh) * 2020-09-11 2022-03-29 济南悟通生物科技有限公司 一种阿贝西利的中间体的合成方法
WO2023090411A1 (ja) 2021-11-19 2023-05-25 塩野義製薬株式会社 心疾患または骨格筋の疾患の治療用医薬
CN115124542A (zh) * 2022-07-08 2022-09-30 河南师范大学 羟基苯取代吡唑酮并吲唑[螺]吡唑酮类化合物的合成方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US984083A (en) 1910-03-28 1911-02-14 William J Faber Floor-plane.
EP0901786B1 (en) 1997-08-11 2007-06-13 Pfizer Products Inc. Solid pharmaceutical dispersions with enhanced bioavailability
HUP0303376A3 (en) 2001-02-28 2007-08-28 Merck & Co Inc Acylated piperidine derivatives as melanocortin-4 receptor agonists, and pharmaceutical compositions containing them and use thereof
PL372887A1 (en) 2002-02-27 2005-08-08 Pfizer Products Inc. Acc inhibitors
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
WO2004092179A1 (ja) 2003-04-14 2004-10-28 Nippon Soda Co. Ltd. スピロ誘導体、製造法および抗酸化薬
JP2005119987A (ja) 2003-10-15 2005-05-12 Ajinomoto Co Inc アシルスルホンアミド誘導体
US20050267221A1 (en) 2004-05-14 2005-12-01 Research Development Foundation Use of curcumin and analogues thereof as inhibitors of ACC2
CA2568056A1 (en) 2004-05-25 2005-12-08 Pfizer Products Inc. Tetraazabenzo[e]azulene derivatives and analogs thereof
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
AU2006270145B2 (en) * 2005-07-19 2011-04-14 Msd K.K. Spirochromanone derivatives as acetyl coenzyme a carboxylase (ACC) inhibitors
CA2617042A1 (en) * 2005-07-29 2007-02-01 Takeda Pharmaceutical Company Limited Spiro-cyclic compound
DE102006016566B4 (de) * 2005-09-22 2008-06-12 Beru Ag Zusammengesetzter Leiter, insbesondere für Glühkerzen für Dieselmotoren
AU2006316626A1 (en) 2005-11-18 2007-05-31 Merck Sharp & Dohme Corp. Spirohydantoin aryl CGRP receptor antagonists
CN101384568B (zh) 2006-02-15 2012-12-12 雅培制药有限公司 乙酰辅酶a羧化酶(acc)抑制剂及其在糖尿病、肥胖症和代谢综合征中的应用
AU2007326950B2 (en) * 2006-11-29 2010-10-14 Pfizer Products Inc. Spiroketone acetyl-CoA carboxylase inhibitors
PE20081559A1 (es) * 2007-01-12 2008-11-20 Merck & Co Inc DERIVADOS DE ESPIROCROMANONA SUSTITUIDOS COMO INHIBIDORES DE ACETIL CoA CARBOXILASA
WO2008102749A1 (ja) 2007-02-20 2008-08-28 Takeda Pharmaceutical Company Limited 複素環化合物
CN104356136A (zh) * 2007-04-12 2015-02-18 辉瑞大药厂 作为蛋白酶c抑制剂的3-酰氨基-吡咯并[3,4-c]吡唑-5(1h,4h,6h)甲醛衍生物
WO2009014455A1 (en) * 2007-07-20 2009-01-29 Mark Jonathon Brownlee Email response time expectation system
US7981904B2 (en) * 2008-03-20 2011-07-19 Takeda Pharmaceutical Company Limited Acetyl CoA carboxylase inhibitors
EP2297163B1 (en) * 2008-05-28 2015-07-08 Pfizer Inc. Pyrazolospiroketone acetyl-CoA carboxylase inhibitors
EP2297164A1 (en) * 2008-05-28 2011-03-23 Pfizer Inc. Pyrazolospiroketone acetyl-coa carboxylase inhibitors
EP2307422B1 (en) 2008-07-04 2014-03-26 Msd K.K. Novel spirochromanone carboxylic acids
WO2010008521A1 (en) * 2008-07-14 2010-01-21 Cropsolution, Inc. Modulators of acetyl-coenzyme a carboxylase and methods of use thereof
PT3061760T (pt) * 2008-09-18 2018-01-04 Auspex Pharmaceuticals Inc Derivados da benzoquinolizina deuterada como inibidores de transportador de monoamina vesicular 2
AP3283A (en) * 2009-11-10 2015-05-31 Pfizer N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors
WO2011058473A1 (en) 2009-11-10 2011-05-19 Pfizer Inc. N2-pyrazolospiroketone acetyl-coa carboxylase inhibitors
WO2012042433A1 (en) * 2010-09-30 2012-04-05 Pfizer Inc. N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS
MX348860B (es) * 2011-04-22 2017-06-30 Pfizer Derivados de pirazoloespirocetona para usarse como inhibidores de acetil-coa carboxilasa.

Also Published As

Publication number Publication date
US8288405B2 (en) 2012-10-16
TN2012000192A1 (fr) 2013-12-12
US9139587B2 (en) 2015-09-22
IL219373A0 (en) 2012-06-28
CA2778886A1 (en) 2011-05-19
JP5114610B1 (ja) 2013-01-09
EP2676958B1 (en) 2015-07-01
CN102695708A (zh) 2012-09-26
CU24077B1 (es) 2015-03-30
EP2676958A1 (en) 2013-12-25
CN102695708B (zh) 2014-10-15
HK1173724A1 (en) 2013-05-24
DOP2012000128A (es) 2012-08-31
PL2499139T3 (pl) 2014-04-30
UY33020A (es) 2011-06-30
JP2013510192A (ja) 2013-03-21
SI2499139T1 (sl) 2014-01-31
EA201290191A1 (ru) 2012-12-28
US8507681B2 (en) 2013-08-13
AU2010317501B2 (en) 2013-06-06
CL2012000999A1 (es) 2012-07-20
AP2012006269A0 (en) 2012-06-30
CO6541569A2 (es) 2012-10-16
EA020153B1 (ru) 2014-09-30
ZA201204231B (en) 2013-02-27
US8802690B2 (en) 2014-08-12
PE20121469A1 (es) 2012-11-01
HRP20140025T1 (hr) 2014-02-14
ES2444543T3 (es) 2014-02-25
PT2499139E (pt) 2014-02-10
RS53156B (en) 2014-06-30
ECSP12011880A (es) 2012-07-31
EP2499139B1 (en) 2013-12-11
CU20120071A7 (es) 2013-05-31
AP3283A (en) 2015-05-31
KR20140034919A (ko) 2014-03-20
AU2010317501A1 (en) 2012-05-17
WO2011058474A8 (en) 2012-04-26
NZ599815A (en) 2013-04-26
IL219373A (en) 2014-04-30
US20130030181A1 (en) 2013-01-31
MA33734B1 (fr) 2012-11-01
EP2499139A1 (en) 2012-09-19
US20130296319A1 (en) 2013-11-07
DK2499139T3 (da) 2014-01-27
AR078944A1 (es) 2011-12-14
EP2947082A1 (en) 2015-11-25
US20140288111A1 (en) 2014-09-25
TWI394756B (zh) 2013-05-01
UA102336C2 (uk) 2013-06-25
KR101550557B1 (ko) 2015-09-04
NI201200089A (es) 2012-08-20
CA2778886C (en) 2014-01-07
BR112012011072A2 (pt) 2017-06-20
GEP20146169B (en) 2014-09-25
CR20120190A (es) 2012-05-24
WO2011058474A1 (en) 2011-05-19
MX2012005429A (es) 2012-06-19
TW201127838A (en) 2011-08-16
KR101478517B1 (ko) 2015-01-02
KR20120099460A (ko) 2012-09-10
US20110111046A1 (en) 2011-05-12

Similar Documents

Publication Publication Date Title
HN2012000973A (es) INHIBIDORES DE N1-PIRAZOLOESPIROCETONA ACETIL-CoA CARBOXILASA
CR20130464A (es) Inhibidores sustituidos de acetil-coa carboxilasa
CU20140025A7 (es) Pirimidinas anilladas sustituidas
CL2013003638A1 (es) Compuestos inhibidores de metaloenzimas; composición que comprende dichos compuestos; uso de la composición para tratar o prevenir una enfermedad asociada a metaloenzimas en plantas; uso para inhibir metaloenzimas en microorganismos y tratar un trastorno fúngico en plantas.
HN2010001920A (es) Dihidropirazolonas sustituidas como inhibidores de hif- propil-4-hidroxilasa
UY32110A (es) Inhibidores de aminopirimidina de los receptores de histamina para el tratamiento de una enfermedad
UY32111A (es) Inhibidores heterociclicos de los receptores de histamina para el tratamiento de una enfermedad
BR112012007747A2 (pt) Compostos heterocíclicos úteis como inibidores de pdk1, sua composição farmacêutica e seus usos
CR20110560A (es) Métodos de tratamiento para tumores sólidos
DOP2013000211A (es) Ciclopropilaminas como inhibidores de desmetilasa 1 especifica de lisina
CO6311079A2 (es) Derivados de aminodihidrotiazina como inhibidores de la enzima bace para el tratamiento de la enfermedad de alzheimer
UY33694A (es) ?inhibidores de n1/n2-lactama acetil-coa carboxilasa?.
HN2009001597A (es) 4-aril-1, 4-dihidro-1,6-naftiridinamidas sustituidas y su uso
HN2011003139A (es) Antagonistas de trayectoria de erizo de ftalazina disustituida
UY33271A (es) Inhibidores heterocíclicos de los receptores de histamina para el tratamiento de una enfermedad
UY33272A (es) Inhibidores heterocíclicos de los receptores de histamina para el tratamiento de una enfermedad
BRPI0917017A2 (pt) inibidores de pirrol de s-nitrosoglutationa redutase como agentes terapêuticos
HN2010002518A (es) Composicion farmaceutica que comprende una sal de estroncio, vitamina d y una ciclodextrina
UY31228A1 (es) Ariloxazoles sustituidos y su uso
CR20110046A (es) Amidofenoxiindazoles utiles como inhibidores de c-met
SV2010003593A (es) Nuevos herbicidas
CR10949A (es) Compuestos triciclicos, composiciones y procedimientos
CR20130024A (es) Compuestos heterocíclicos fusionados
UY32849A (es) Inhibidores heteroarilicos biciclicos de pde4
BR112014000634A2 (pt) métodos para tratamento de incontinência associada com atividade sexual